Gsk Share Discussion Threads

[tradermichael] 27/11/2023 08:41

GSK has disclosed encouraging results from its phase III DREAMM-7 trial, revealing that Blenrep (belantamab mafodotin) has shown effectiveness as a second-line treatment for relapsed or refractory multiple myeloma.

[alibizzle] 23/11/2023 16:31

Hopefully can back to £15-16 in January 2024. It's underperformed for way too long . Still think haleon will be subject to a takeover in 2024 so my considerable GSK shares losses can perhaps be mitigated with share price jump from there . Basically clutching at straws

[tradermichael] 23/11/2023 12:03

A large number of new entities at Phase III trials. Many are destined to be first/best 'in class'. This will eventually be recognised by the 'market'.

[beergut] 22/11/2023 10:14

If only they could stop inventing new drugs. It drives the price down every time.

[tradermichael] 22/11/2023 08:02

GSK3437949 Malaria next generation (fractional dose)?

[giltedge1] 21/11/2023 16:07

Word on the street have a game changing malaria vacine in final trails.

[blackhorse23] 17/11/2023 10:28

Money moving to APH

[panache1] 16/11/2023 11:43

From now ?

[panache1] 16/11/2023 09:09

Is this as low as it's going today ex div ? That would be good

[rikky72] 15/11/2023 19:11

So I've held since 2001 and I can honestly only think of the following when sentiment was good:- 2001 - Advair launch - 2006 - some excitement about some new respiratory drugs - 2012/13 - excitement about the 'big 6' in the pipeline (mixture of respiratory, HIV and CVS drugs)- 2017 - new CEO bounce? :)- 2019/20 - Run of good results and pipeline looking better - 2022 - Riding high until demerger and double whammy of lower divi and Zantac litigation Obviously this is from memory and not perfect but I would say in that 23 year timeline I've been following it that sentiment has been poor at least two thirds of that time..

[anhar] 15/11/2023 12:02

For most of its existence, sentiment towards GSK has been very poor. Doesn’t look like that’s changing anytime soon. Definitely frustrating though.

I've held since dinosaurs roamed and your comment is accurate though I wouldnt say the poor sentiment has been "for most of its existence". Hard to see now but long ago there was a time whn the share was quite highly regarded as shown by a yield of only about 2%.

However the poor sentiment of more recent years is not baseless. For some time the company has delivered poor financial results, not helped by increasingly monstrous debt. So even an upturn in its fortunes will take a while to impress cynical institutional investors who I think have long held, and rightly, a less than optimistic opinion of the company.

The best thing imo they have done recently is the HLN demerger and I continue to hold my allocation. I'm primarily an income investor but if I look at the capital performance over the decades, it's only because HLN is showing a profit that my combined holding is showing a tiny profit over the original cost of old GSK after all these years, as new GSK is showing a loss over the demerger adjusted price.

As for income, which is my reason for holding equities at all, that has also been trashed following the demerger.

I'm guessing that sooner or later this crock GSK will probably be turned round, something that management has singularly failed to do for many years. Not sure I'll live that long though...

[abdullla] 15/11/2023 09:37

GSK share price going against the rise in the Ftse,getting ready for the double drop tomorrow due to X-div

[montyhedge] 14/11/2023 18:41

You can't argue with facts GSK shareprice below what it was 30 years ever since they merged with Smith Kline Beecham.

[rikky72] 14/11/2023 16:21

For most of its existence, sentiment towards GSK has been very poor. Doesn't look like that's changing anytime soon. Definitely frustrating though.

[spoole5] 14/11/2023 16:04

Never seen a share react so badly to good news

[abdullla] 14/11/2023 14:42

Could end up in a disaster

[abdullla] 13/11/2023 14:36

Diving into red soon

[tradermichael] 13/11/2023 12:19

GSK said it has received a positive opinion recommending the approval of its blood-cancer treatment momelotinib from the European Medicines Agency.

The British pharmaceutical giant said the decision on marketing authorization in the EU is expected by early 2024.

The positive opinion was adopted by the Committee for Medicinal Products for Human Use--or CHMP--of the European Medicines Agency, and is one of the final steps prior to marketing authorization decision by the European Commission.

If approved, momelotinib would be the only medicine in the EU specifically for both newly diagnosed and previously treated patients with myelofibrosis--a rare type of blood cancer--and moderate to severe anaemia, that addresses enlarged spleen and symptoms.

[theoriginalwonderstuff] 10/11/2023 15:50

I agree R72. The problem is that this is exactly where it was a decade + ago... It's like a dying dodo which needs to be put out of its misery!!

[rikky72] 10/11/2023 15:35

It's not going to happen. Their near term pipeline is not compelling enough, execution of this scale is always messy and the final nail is that any would be acquirer would face resistance from the UK government.But hopefully things will perk up for it within a year or so organically. There is certainly potential there.

[theoriginalwonderstuff] 10/11/2023 11:03

Are there any circumstances in which someone might launch a takeover bid for GSK?? It's been languishing for years. Is it too much of a behemoth to be taken over? Too unruly? Too big?? Or just too much of a basket case?!

[patientcapital] 03/11/2023 14:53

These gyrations happen from time to time. Kicking when down is good sport for some. Good luck to them.

[tradermichael] 03/11/2023 13:10

Take a good, long look at GSK's new product pipeline. Many late stage oncology drugs there, specifically employing monoclonal antibody science - these and many others (vaccines included) are first or best in class.

[cumnor] 02/11/2023 23:28

Patient Capital, the real growth story here is baloney and Monty points to share price performance over 20+ years as proof pudding (it's not the markets fault). Vaccines don't, unfairly imo, cut the same ice as blockbuster statins, weight suppressants or oncology drugs.
Until she delivers GROWTH investors want dividends and too many are giving 8% (lgen, bdev, hbr etc and have been decimated but are still excellent companies) to make GSK's (pipedream) 3.95% less than tempting.
The day's of pharma being a ;special' case are gone-investors want return for risk and Emma is not quite getting it. She needs to give 6% (74P) to maintain current share price or see a drift to low £12s as investors opt for safe treasuries yielding 5%+ which will be available for the next year. Otherwise she needs to pack her bags asap. imo